☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Lilly
Lilly to Acquire Sigilon Therapeutics for Over $300M to Enhance its Cell Therapy Business for the Treatment of Type 1 Diabetes
June 30, 2023
Lilly Presented P-II Trial Results of Orforglipron for the Treatments of Adults with Obesity or Overweight at American Diabetes As...
June 26, 2023
Lilly to Acquire Akouos for ~$610M
October 18, 2022
Lilly Entered into an Exclusive License Agreement with D. E. Shaw Research to Develop and Commercialize DES-7114 for Immunological...
June 14, 2022
Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcera...
May 24, 2022
Lilly's Mounjaro (tirzepatide) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes
May 16, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.